FK-506 inhibits Ca2+-dependent transcription of lymphokine genes in T cells, and thereby acts as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear whether these immunosuppressive and toxic effects result from interference with rehted biochemical processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant cytosolic protein with cis.trans peptidyl-prolyl isomerase activity (PPlase) activity. Because rapamycin (RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting T cell responses to lymphokines, such an interaction with FKBP-12 is not suf~cient to mediate immunosuppression. Recently, it was found that the complex of FKBP-12 with FK-506, but not with RAP, inhibits the phosphatase activity of calcineurin. Here, we used b685,818, the C18-hydroxy, C21-ethyl derivative of FK-506, to explore further the role of FKBP-12 in the immunosuppressive and toxic actions of FK-506. Although b685,818 bound with high af~nity to FKBP-12 and inhibited its PPlase activity, it did not suppress T cell activation, and, when complexed with FKBP-12, did not affect calcineurin phosphatase activity. However, b685,818 was a potent antagonist of the immunosuppressive activity of both FK-506 and RAP. Moreover, L-685,818 did not induce any toxicity in dogs and rats or in a mouse model of acute FK-506 nephrotoxicity, but it blocked the effect of FK-506 in this model. Therefore, FK-506 toxicity involves the disruption of biochemical mechanisms related to those implicated in T cell activation. Like immunosuppression, this toxicity is not due to the inhibition of the PPlase activity of FKBP-12, but may be linked to the inhibition of the phosphatase activity of calcineurin by the drug FKBP-12 complex.
F
K-506, rapamycin (RAP) 1, and cyclosporin A (CsA), define a class of immunosuppressive natural products that have in common the ability to inhibit T lymphocyte activation by interfering with intraceUular signaling mechanisms (1, 2) . However, these agents affect different biochemical pathways within the cascade of events that culminate in the expression ofT cell effector functions. Both FK-506 and CsA disrupt T cell signaling pathways associated with a rise in the concentration of intracellular Ca 2+ (3, 4) , and this results in the inhibition of the transcription of a family of early activation genes, including IL-2 and IL-4 (5-7). In con-1 Abbreviations used in this paper: BUN, blood urea nitrogen; CsA, cyclosporin A; Cyp, cyclophilin; FKBP-12, FK-binding protein-12; PPIase, peptidyl-prolyl isomerase activity; and RAP, rapamycin. trast, RAP does not inhibit Ca2+-dependent lymphokine gene expression (5, 3) , but impairs the response of T cells to growth-promoting lymphokines (3) . Furthermore, FK-506 and RAP potentiate the immunosuppression induced by CsA (8, 9) , whereas, under certain conditions, they antagonize each other's immunosuppressive action (9) .
Despite thdr exquisite specificity for certain steps in T signal transduction, these immunosuppressants have significant in vivo toxicity. The adverse effects of FK-506 and CsA are very similar an include neurotoxicity and nephrotoxicity (10, 11) , whereas RAP exerts little nephrotoxicity, but induces vasculitis (12) and myocardial necrosis (13) . These toxic manifestations are of particular concern as they impose severe limitations in the potential therapeutic application of these immunosuppressants. At present, it is unclear whether ira-munosuppression and toxicity are mediated through the alteration by the drugs of similar biochemical processes in different cell types.
At the biochemical level, FK-506 and CsA interact with two distinct families of intraceUular proteins, termed FKbinding proteins (FKBPs) (14) and cyclophilins (Cyps) (15) , respectively. Despite its contrasting biological activity profile, RAP binds to the same FKBP protein family as FK-506 (16, 17) . The two major forms of each of these receptor types, FKBP-12 and Cyp A, are peptidyl-prolyl cis-trans isomerases (PPlases), and catalyze the interconversion of the c/s and trans rotamers of the peptidyl-prolyl amide bonds of peptide and protein substrates (16, 18, 19) . FK-506, RAP, and CsA inhibit the PPIase activity of their respective binding proteins (16, (18) (19) (20) . However, inhibition of this enzymatic activity is not sufficient to explain the biological activities of these immunosuppressants. We demonstrated that a CsA analog that inhibited Cyp A PPlase activity was neither immunosuppressive nor nephrotoxic, whereas another analog, which had little or no activity as a PPlase inhibitor, exhibited immunosuppressive activity (21) . The similar potencies of FK-506 and RAP in inhibiting the PPlase activity of FKBP-12 also suggested a dissociation between this inhibition and the mode ofimmunosuppressive action of the macrolides (22) . Moreover, a synthetic compound (506BD), corresponding to the portion of the FK-506 molecule that binds to FKBP-12 (23) , was found to block the PPIase activity of this protein without exerting significant immunosuppression (22) .
The discovery that the molecular complexes formed between FK-506 and FKBP-12 or between CsA and Cyp A bind to the Ca 2+-and calmodulin-dependent serine/threonine phosphatase, calcineurin (24, 25) , and inhibit its enzymatic activity (26) , may explain how these compounds exert their immunosuppressive effects. Since a RAP:FKBP-12 complex does not inhibit calcineurin phosphatase activity, the observations also provide an explanation for the mechanistic similarity between FK-506 and CsA. However, because the nonimmunosuppressive compound 506BD was found capable of inhibiting calcineurin phosphatase activity by up to 40% (26) , additional studies with other macrolide analogs appear necessary to establish the relevance of these in vitro effects to immunosuppression.
In the present work, we describe b685,818, a novel nonimmunosuppressive FK-506 relative, and use this molecule as a probe to further explore the mechanisms of action of FK-506 and RAP. b685,818 is the C18-hydroxyl derivative of L-683,590, which differs from FK-506 by a single allyl to ethyl substitution at the C21 position of the macrolide ring (27) . We found that b685,818 binds to FKBP-12 and inhibits its PPlase activity. However, the FKBP-12:b685,818 complex was unable to inhibit calcineurin phosphatase activity, in contrast to the FKBP-12:b683,590 complex which was half as active as the FKBP-12:FK-506 complex in this assay. Moreover, L-685,818 behaved as a potent competitive antagonist of the inhibitory effects of both FK-506 and RAP, but not of CsA, in models of T cell activation in vitro. Although L-685,818 had no detectable toxicity in vivo, it proved to be an effective antagonist of FK-506, but not of CsA, in a murine model of drug-induced nephrotoxidty. Altogether, these studies with L-685,818, clearly show that the inhibition of FKBP-12 PPIase activity is not involved in either the immunosuppressive or toxic effects of FK-506. Moreover, there exists a mechanistic relationship between these two types of biological effects of the drug, that may be linked to the inhibition of calcineurin phosphatase activity.
Materials and Methods
Mice. Female C57B1/6 and BALB/c mice (6-12-wk-old) were obtained from the Jackson Laboratory (Bar Harbor, ME) or from Taconic Farms (Germantown, NY), and maintained under specific pathogen-free conditions until use.
Reagents Cell Cultures. Splenic T cells from C57B1/6 mice were isolated by nylon wool separation as previously described (3). The DO-11.10 T cell hybridoma (29) was provided by Dr. Philippa Marrack (National Jewish Center for Immunology and Respiratory Medicine, Denver, CO). The YAC-1 T cell lymphoma was obtained from the American Type Culture Collection (Rockville, MD). Cells were grown in culture medium made up of RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated FCS, 2 mM glutamine, 1 mM sodium pyruvate, 2 • 10-5 M 2-ME, and 50 #g/ml gentamycin. Microcultures of splenic T cells were set up in flat bottomed 96-well plates (Costar Corp., Cambridge, MA). Each well received 200 gl of cell suspension at 106 cells/ml. The T cell activators and various combinations of compounds were set up in triplicate wells. The plates were incubated at 37~ in a humidified atmosphere of 5% CO2-95% air. Cultures were pulsed with [3H]TdR (2 #Ci/well) for the last 4-5 h of a 48-h incubation period and harvested on glass fiber filters. Incorporated radioactivity was measured by using a Betaplate liquid scintillation spectrometer (Pharmacia-LKB, Piscataway, NJ). Cell cultures for analysis of mKNA expression were set up in 25-cm z tissue culture flasks (Coming Glass Works, Coming, NY) maintained in an upright position. DO-11.10 cells (2 x 10 s cells/ml) were stimulated with ionomycin plus PMA in the presence or absence of drugs, and harvested for RNA extraction after 3 h of culture. YAC-1 cells (10 s cells/ml) were incubated with Ibl plus PMA in the presence or absence of drugs, and RNA was extracted after 20 h of culture.
RNA Extraction and Slot Blot Analysis. Total cellular RNA was isolated using RNAzol (Cinna/BioTeck, Friendswood, TX). RNA samples were blotted onto nitroceUulose filters using a slot-blot Minifold II apparatus (Bio-Rad Laboratories, Richmond, CA). The cDNA probes were labeled with [32p]dCTP to high specific activity using a random primed DNA labeling kit (Boehringer Mannhelm, Indianapolis, IN). R.NA blots were prehybridized and hybridized with the probes and autoradiographed using Hyperfilm-ECL (Amersham Corp., Arlington Heights, IL).
FKBP Binding Assay. Human FKBP-12 was purified as previously described (19) . An LH-20 column binding assay (15) 
FKBP-12
PPIase Assay. The PPlase activity of FKBP-12 was assayed as previously described (20) by measuring the c/s to trans isomerization of the proline-phenyhhnine peptide bond in the peptide, Suc-Ala-Leu-Pro-Phe-pNA. Under equilibrium conditions, '-88% of the peptide is present as the trans form and is readily cleaved by chymotrypsin. The remaining 12% of the peptide present in the c/s form is cleaved upon enzymatic conversion to the trans form. The size of conversion was monitored by the change in absorbance at 390 nM because of the release ofp-nitroaniline. The compounds were tested in 4-ml cuvettes containing 2.8 ml of a 70 mM solution of the substrate in assay buffer (35 mM Hepes, pH 7.8, 3% DMSO) to which were added 30/~1 ofa 1.2-mM solution of FKBP-12. Various dilutions of compound in 10/~1 ethanol were added, and the resulting solution was left to reach thermal equilibrium at 10~ for 10 rain. The reaction was initiated by addition of 100 #1 of a 2.2-mM solution of chymotrypsin in 1 mM HCI, and absorbance was recorded. The first order portion of the resulting progress curve was fit to a simple first order rate equation. The rate constants determined from the enzymatic isomerase activity was first corrected for the rate of nonenzymatic isomerization. This value, k~,~hb, divided by the rate constant for the reaction in the absence of inhibitor, k~ ..... l, was plotted as a function of inhibitor concentration. The resulting plot was fit to a model for tight binding inhibition to obtain K1 and [Eo].
Phosphatase Assay of Cakineurin. The assay was modified from the procedures described by Manalan and Klee (30) and Lin et al. (26) . Inhibitor I peptide (28) , which was phosphorylated with 321). labeled ATP (450 cpm/pmol) with the catalytic subunit of cAMPdependent protein kinase, was used as a substrate. The assay buffer consisted of 40 mM Tris-HCl (pH 7.5), 0.1 M NaC1, 6 mM MgC12, 0.1 mM CaC12, 0.1 mg/rrd BSA, and 0.5 mM dithiothreitol. The assay mixture (60/~1) contained 3 nM bovine brain calcineurin (Sigma), 190 nM calmodulin (Sigma), 420 nM recombinant human FKBP-12 and 7/~M ofphosphopeptide. The drug solutions were prepared in DMSO at concentrations of DMSO <0.04% in the final assay mixture. The incubation was carried out at 30~ for 10 min before the reaction was stopped and loaded onto 0.5-ml Dowex AG 50W-X8 (200-800 mesh; Bio-Rad Laboratories)
columns. The level of [32p] eluted from the columns was determined by liquid scintillation radioactivity measurement.
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Toxicological Evaluation ofL685,818 in Dogs and Rats.
Beagle dogs (two males and two females per group) or Sprague-Dawley rats (10 males and 10 females/group) were treated daily for 14 d with L-685,818 or the vehicle only. L685,818 was administered by oral gavage as a suspension in 0.5% methylcellulose, at a dose of 25 mg/kg/d. The animals were observed daily for mortality and clinical signs of drug effect. Body weight and food consumption were also monitored. During the second week of treatment, hematologic and serum biochemical examinations and urinalysis were conducted. For the dog study, plasma drug level determinations were made on the first day of treatment and at study determination. At necropsy, gastrointestinal tract, liver, kidneys, spleen, lymph nodes, and thymus were examined for any gross lesions. Specimen of these tissues were preserved in 10% neutral buffered formalin and examined microscopically using paraffin-embedded and hematoxylin/eosin-stained sections.
Murine Acute Nephrotoxicity Assay. Treatment with the cytochrome P450 inhibitor, SKF-525A (31), was used to enhance the toxicity of FK-506 in BALB/c mice (Koprak, S., and F. Dumont, manuscript in preparation). SKF-525A was dissolved in saline, and a dose of 75 mg/kg was injected intraperitoneally 2 h before intravenous injection of 0.5 ml of the compound or vehicle control solutions. Stock solutions of compounds were made up in ethanol at 65 rag/m1, further diluted in ethanol, and mixed with Cremophor | (BASF, Parsippany, NJ) followed by saline, to give final solutions containing 10% (wt/vol) Cremophor | and 6% ethanol. The vehicle control solution was made up of saline with the same concentrations of Cremophor | and ethanol. The mice received these injections for 2 consecutive d and were killed the following day for autopsy and collection of serum and tissue (kidney, liver) samples. Measurement of blood urea nitrogen (BUN) levels in the serum was done on an autoanalyzer (model 203; Gilford Instrument Laboratories, Inc., Oberlin, OH). Fig. 1 , the chemical structure of b685,818 is closdy related to that of FK-506. L-685,818 was synthesized from I.-683,590, which differs from FK-506 by an ally1 to ethyl substitution at the C21 position (27) . b685,818 also contains a hydroxyl group at the C18 position of the macrolide ring. Consistent with their structural similarity to FK-506, both L-685,818 and I--683,590 bind to FKBP-12 with a high af~nity (Fig. 2 a) . Furthermore, L-685,818 is a potent inhibitor of the PPlase activity of this protein, comparable with FK-506 or RAP (Fig. 2 b) .
Results

L.685,818 Binds to FKBP-12 and Inhibits its PPIase Activity but Does Not Inhibit T Cell Activation. As shown in
In contrast to its activity in these biochemical assays, 1.-685,818 did not inhibit the proliferation of T cells activated by ionomycin plus PMA, even when tested at concentrations up to five orders of magnitude >FK-506 (Fig. 2 c) . Under the same conditions, L-683,590 was only threefold less potent than FK-506, in agreement with earlier studies (27) . I--685,818, at concentrations as high as 25/~M, also had little effect on IL-2 plus PMA-induced T cell proliferation, whereas, as previously reported (3), such a response was suppressed by subnanomolar concentrations of RAP (Fig. 2 d) 
L685,818 Antagonizes the Suppressive E.~ects of FK.506 and RAP on T Cell Proliferative Responses.
These observations, together with our earlier finding of a mutual antagonism between FK-506 and RAP (9), prompted us to examine the possibility that I~685,818 might be a functional antagonist of these macrolides. We first tested whether b685,818 would block the inhibitory effect of FK-506 in ionomycin plus PMAstimulated T cells. FK-506 was used at 1.2 nM, a concentration that suppressed the proliferation by 93-97%, and vatious concentrations of L-685,818 were added simultaneously. As shown in Fig. 4 a, concentrations of L-685,818 >100 nM completely reversed the suppressive effect of FK-506. Therefore, 1,685,818 is a potent antagonist of FK-506 (EDs0 --63.1 _+ 7.2 ruM, mean _+ SEM of 13 experiments). In contrast, L-685,818 failed to reverse the inhibitory effect of CsA in T cell cultures similarly stimulated with ionomycin plus PMA ( Table 1) .
The Schild analysis method is used to determine the affinity of a pharmacological antagonist in a biological system (32), and was employed here to further evaluate the antagonist activity of L-685,818. T cells stimulated with ionomycin plus PMA were cultured in the presence of vafious concentrations of FK-506 either alone or together with increasing concentrations of L-685,818. 
1_,685,818 Reverses the Immunosuppressive E~ects of FK-506 or RAP Even When Added Late into the Cultures. Experiments
were then conducted to define the temporal site of this antagonistic effect of L685,818. Fig. 5 a demonstrates that, when added as late as 6 h after FK-506 in T cell cultures activated with ionomycin plus PMA, b685,818 still fully restored the proliferative response measured at 48 h of culture. L-685,818 also reversed the inhibition of PAP by more than 50% even when added up to 12 h after the latter to cuhures stimulated with Ib2 plus PMA (Fig. 5 b) . Therefore, L-685,818 competes at the level of the functional receptors that mediate the pharmacologic action of the immunosuppressants, rather than at the level of a transport mechanism necessary for entry of the macrolides into the cell. PMA. Fig. 6 a shows that Ib2 mRNA was detectable 3 h after activation and was inhibited by FK-506 in a dosedependent manner. L685,818 had no effect on this induction of ID2 mRNA expression, but it blocked the inhibitory effect of FK-506. In a different modal of lymphokine gene regulation, the induction of IFN-'y mRNA by IL-1 plus PMA in the YAC-1 T cell lymphoma (33), PAP was inhibitory at concentrations as low as 1 nM (Fig. 6 b) . b685,818, tested at 12/~M, did not inhibit IFN-3, mRNA expression and totally restored this expression in PAP-treated cultures.
1-,685,818 Antagonizes the Suppressive Effects of FK-506 and
1..685,818 Is Not Toxic in Dogs andRats.
Based on the afor~ mentioned data, b685,818 appeared as an excellent tool to address the question of the mechanistic relationship between F~-506 immunosuppression and toxicity. First, we investigated L-685,818 at doses as high as 25 mg/kg/d, which gave plasma drug levels >2 /xg/ml. Similarly, oral administration of D685,818 in rats for 2 wk at 25 mg/kg/d, failed to cause the nephrotoxicity or behavioral changes that have been observed with FK-506 (10, 11). Therefore, b685,818 is devoid of the toxicity known to be associated with FK-506.
L685,818 Blocks the Nephrotoxic Action of FK-506.
To examine the possibility that L-685,818 could antagonize FK-506-induced toxicity, we used an acute model in BALB/c mice, where the nephrotoxic potential of FK-506 was enhanced by cotreatment of the animals with the inhibitor of cytochrome P450, SKF-525A (31) . Consistent with the recently demonstrated role of P450 enzymes in the metabolism of FK-506 (35), we found that SKF-525A augmented the serum level of FK-506 (not shown). Under these conditions, two daily intravenous injections of FK-506 in doses ranging from 3.1 to 12.5 mg/kg were sufficient to induce a significant elevation of BUN levels. I.-683,590 (50 mg/kg) was also found to raise BUN concentration, whereas RAP (100 mg/kg) had no effect on this parameter, although it caused mortality (Table  2 ). In contrast, the same protocol of treatment with 100 mg/kg of b685,818 did not produce any increase of BUN or mortality (Table 2 and Fig. 7) . It is most interesting that administration of this high dose of b685,818, together with toxic doses of FK-506, prevented almost completely the rise in BUN observed with FK-506 alone (Fig. 7 a) . The dosedependent nature of the antagonism is demonstrated in Fig.  7 b, where the animals were given a constant dose of FK-506 and varying doses of I~685,818. Therefore, L-685,818 is a potent antagonist of the acute nephrotoxic effect of FK-506 in this murine model Additional experiments (not shown) demonstrated that b685,818 does not block CsA-mediated nephrotoxicity. 
Discussion
The present study exploits the unique pharmacological properties of b685,818 to investigate the mechanism of action of FK-506 with respect to its biochemical target for immunosuppression, and the relationship between this target and toxicity, b685,818 differs from FK-506 at two positions. Although the aUyl to ethyl substitution at the C21 position results in a two to threefold loss in immunosuppressive potency, it is the addition of a hydroxyl group at the C18 position of the macrolide ring that converts the molecule to an antagonist. Recent x-ray crystallographic and nuclear magnetic resonance studies indicate that I.-685,818 associates with FKBP-12 through its pipecolic acid portion, in a manner identical to FK-506 (Becker, J., manuscript in preparation). Hence, it is not surprising that FK-506 and L-685,818 have equivalent activities in binding to FKBP-12 and in inhibiting its PPlase activity, since it is their common "face" that is responsible for these activities. Such observations are consistent with earlier studies using 506BD and RAP (22) .
The observation that the physical interaction with FKBP-12 and the inhibition of PPIase may be necessary but not sufficient for immunosuppression has led to the hypothesis that the drugs must interact with other cellular components to disrupt the signaling processes of T cell activation (1, 2) . This hypothesis is supported by the recent finding that the corn- 757 Dumont et al. this activity with a potency approximatdy twofold lower than FK-506. This demonstrates a clear-cut corrdation between the ability of the drugs complexed to FKBP-12 to interfere with the phosphatase activity of calcineurin and their ability to suppress T cell activation induced in a Ca2+-dependent manner. Such a correlation suggests that the inhibition of caldneurin enzymatic function by the FKBP-drug complex may be involved in the mechanism of immunosuppressive action of the drugs. Although a similar conclusion had been made based on studies with RAP (26), the strict concordance between the biochemical and cellular observations produced by a subtle structural change, such as the 18-hydroxy substitution, further solidifies this model. Are the molecular entities defined in the current in vitro caldneurin assay system the relevant members of the complex that mediate immunosuppressive activity in vivo? There are several reasons to consider this question. First, the in vitro system used in both the present and previous (26) studies is based on the interaction of heterologous proteins (bovine calcineurin and calmodulin with human FKBP-12). Second, the existence of several isoenzymes of calcineurin (25) Pharmacological experiments with CsA analogs also suggested that Cyp A may not be the member of this family to mediate the immunosuppressive activity of CsA (21). Thus, whereas genetic studies dearly put calcineurin in the drug-sensitive signal transduction pathway, experiments performed to date do not permit us to identify which FKBP family member is the most relevant effector of calcineurin complex formation in vivo.
The identification ofb685,818 as the most potent antagonist of both FK-506 and RAP-mediated immunosuppression synthesized to date has allowed us to explore the nature of the functional receptor of these compounds from a different perspective. Sehild ~n~lysis was used to demonstrate that b685,818 interacted with a single receptor species when either FK-506 or RAP was used as the agonist. Furthermore, since b685,818 could be added to the cultures several hours after FK-506, and since FK-506 is known to penetrate and reach equilibrium within the cells in <20 rain (14) , we concluded that the antagonism of b685,818 does not reflect inhibition of a transport mechanism. The most straightforward conclusion from these data is that b685,818 antagonizes FK-506 and RAP through their interaction with a common cellular receptor, a notion already suggested by the fact that the two drugs antagonize each other's action with similar potencies (9) . More through analysis suggests alternative possibilities, however. The affinities derived by Schild analysis (4-8 riM) differ significantly from those estimated from FKBP-12 competitive binding measurements (0.7 riM). This diffgrence may be due to relative abundance of the relevant drug receptor within the cell. However, given the fact that the intracellular concentration of FKBP-12 is '~5-10/~M (Dumont, F. et al., manuscript in preparation), one might expect that even larger concentrations of I.-685,818 would be required to observe antagonism and that the antagonism might be noncompetitive. Taken together, Ka estimates derived from the Sehild analysis are not entirely consistent with the assumption that the antagonist and agonists are distributed uniformly within the FKBP-12 cytosolic receptor pool. Indeed, FK-506 and RAP may interact with receptors that are in lower abundance than FKBP-12, or may bind preferentially to a distinct subset of FKBP-12 molecules within the cell. Therefore, although FKBP-12 appears as the most plausible intracellular target for these compounds, we cannot exclude the possibility that another known, or as yet undiscovered FKBP may be involved.
The present study provides important insights into the relationship between the immunosuppressive and toxic effects of FK-506. Along with its lack of immunosuppressive activity, I.-685,818 did not elicit any of the side effects known to occur after FK-506 treatment in several animal species, including the gastrointestinal pathology seen in dogs (34) and the nephrotoxicity observed in rats (11) . Using a mouse model where the nephrotoxic effect of FK-506 was enhanced by coadministration of the I}450 inhibitor SKF-525A (31), we found that L-685,818 produced little or no elevation of BUN, even when given at doses 5-10-fold greater than nephrotoxic doses of FK-506. Since interfering with FK-506 metabolism potentiates the toxicity of the drug, it is likely that the parent compound, rather than metabolites, may be primarily responsible for the induction of nephrotoxicity. Furthermore, the use of an inhibitor of macrolide metabolism also minimizes the possibility that b685,818 could be modified in vivo. The most striking observation made with this modal, however, is that b685,818 reversed the nephrotoxic action of FK-506 in a dosedependent manner.
The finding that the toxic effects of FK-506 can be reversed by the same antagonist that blocks FK-506 immunosuppression strongly suggests that the mechanisms of immunosuppression and toxicity are related. FK-506 may therefore affect biochemical processes that are part of signal transduction pathways shared in common by lymphoid calls and by nonlymphoid calls in the target toxicity organs. As for immunosuppression, it is unlikely that these processes involve inhibition of PPlase activity, which is similar to the conclusion reached in an analysis of CsA analogs (21) . Instead, the toxicity of FK-506 may be linked to the ability of the drug-FKBP-12 complex to inhibit the phosphatase activity of calcineurin. This conclusion may also explain why FK-506 and CsA share such similar patterns of toxicity (11) .
Since FKBPs, Cyps, and calcineurins are widely distributed, it may be surprising that FK-506 and CsA do not produce even more toxicity. There may be several reasons for the apparent sdectivity of the drugs. Although calcineurin is present in a variety of tissues, it differs in abundance and isoenzyme distribution pattern (25) , and may have diverse roles in the physiology of the cells. The substrates for calcineurin may also differ among cells. In addition, selectivity could be related to the tissue distribution of related FKBPs that would confer the appropriate aff~ty and fimctional ability of the drug complex to interfere with calcineurin. Nevertheless, the finding that immunosuppression and toxicity of FK-506 are mechanistically related will make it difficult to dissociate the immunosuppressive activity and toxic effects of molecules that use such common biochemical pathways.
